

# METABOLIC LESSONS FROM GENETICALLY LEAN MICE\*

---

Marc L. Reitman

*Diabetes Branch, National Institute of Diabetes and Digestive and Kidney Diseases,  
NIH, Bethesda, Maryland 20892-1770. Current address: Merck Research Laboratories,  
Rahway, New Jersey 07065-0900; e-mail: marc\_reitman@merck.com*

**Key Words** lipotrophy/lipodystrophy, insulin resistance, diabetes, leptin, energy homeostasis

■ **Abstract** Different types of lean mice have been produced by genetic manipulation. Leanness can result from deficiency of stored energy or a lack of adipocytes to store the lipid. Mice lacking functional adipocytes are usually insulin resistant and have fatty livers, and elevated circulating triglyceride levels. Insulin resistance may result from the lack of adipocyte hormones (such as leptin) and increased metabolite (such as triglyceride) levels in nonadipose tissue. Mice with depleted adipocyte triglyceride levels typically are insulin sensitive and have normal or low liver and circulating triglycerides. Mechanisms to produce depleted adipocytes include increased energy expenditure by peripheral tissues, peripheral mechanisms to decrease food intake, and altered central regulation of these processes.

## CONTENTS

PHYSIOLOGY OF ENERGY HOMEOSTASIS .....	460
TYPES OF LEAN MICE .....	461
EXPERIMENTAL ASSESSMENT OF ALTERED	
ADIPOSIITY AND ITS CAUSES .....	465
Measuring Adiposity .....	465
Scaling Measurements to Body Weight .....	465
Importance of Ambient Temperature in Smaller Mammals .....	466
Effects of Sex, Age, Diet, and Background Genotype .....	466
SPECIFIC EXAMPLES OF GENETICALLY LEAN MICE .....	467
Peripherally Driven Increased Energy Expenditure via Muscle .....	467
Peripherally Driven Increased Energy	
Expenditure via Adipose Tissue .....	468
Increased Energy Expenditure via	
Multiple or Unknown Tissues .....	469

---

\*The US Government has the right to retain a nonexclusive, royalty-free license in and to any copyright covering this paper.

Central Nervous System–Mediated Lean Mice .....	471
Peripherally Decreased Energy Availability .....	472
Special Cases: Confusing or Insufficient Information .....	473
Abnormal Adipocyte Biochemistry .....	473
White Adipose Tissue Ablation .....	474
CONCLUSIONS .....	475

## PHYSIOLOGY OF ENERGY HOMEOSTASIS

The major form of stored energy in mammals is triacylglycerol, commonly referred to as triglyceride. With its energy density of 9 kcal/g, triglyceride is a very efficient way to stockpile energy. Specialized fat-storing cells, adipocytes, are the body's principal storage site and number about half the total cells but the vast majority of the mass of white adipose tissue (WAT). Triglyceride can also be stored in sites other than adipose tissue, such as the liver. A second type of adipose tissue is brown adipose tissue (BAT), whose principal function is to generate heat. BAT heat generation is important in small mammals such as mice, rats, and human infants but is thought to have little or no role in larger mammals such as adult humans. In addition to energy storage and heat generation, adipose tissue also has endocrine functions. Adipose peptide hormones include leptin, adiponectin/ACRP30/AdipoQ, resistin/FIZZ3/ASDF, tumor necrosis factor- $\alpha$ , interleukin 6, plasminogen activator inhibitor 1, and angiotensinogen. In addition, free fatty acids probably have hormone-like actions because some appear to be ligands for the PPAR family of transcription factors.

A lean mouse is the result of a relative excess of energy expenditure over energy intake. Increased energy expenditure can be mediated by peripheral mechanisms such as by directly increasing substrate oxidation in muscle, fat, or other tissues. Decreased energy availability can also occur by peripheral mechanisms, such as by reduced intestinal absorption. The central nervous system (CNS), particularly the hypothalamus, regulates energy intake and expenditure (87). In the past decade our knowledge of the central pathways for regulating energy homeostasis has gone from prehistoric to pre–Industrial Revolution. Mutant mice have led the way, pointing to relevant proteins and neuronal pathways. Thankfully, the molecules and pathways identified in rodents are highly conserved in humans and the murine information is generalizable.

Inputs to the CNS include the hormones leptin and insulin, energy molecules such as glucose and fatty acids, and signals transmitted via peripheral nerves. Leptin is produced by adipocytes in proportion to fat mass and is a major input to the hypothalamus, particularly the arcuate nucleus. Arcuate leptin-responsive neurons include those expressing NPY/AGRP and POMC/CART. CART and  $\alpha$ MSH, a POMC cleavage product that stimulates melanocortin-3 and melanocortin-4 receptors, act on paraventricular nucleus neurons, eventually inhibiting food intake. NPY, presumably binding to Y1 and Y5 receptors, and agouti-related protein (AGRP), which antagonizes  $\alpha$ MSH binding, stimulate food intake and decrease

energy expenditure. In the lateral hypothalamus, melanin concentrating hormone (MCH) is a neuropeptide that is a potent stimulator of food intake and metabolic efficiency. As discussed below, mutant mice have also identified VGF and muscarinic M3 receptors as important in the food intake/metabolic efficiency regulatory network.

## TYPES OF LEAN MICE

Below we discuss about 40 genetically lean mice (we have not included lean mice produced by environmental manipulation) (Table 1). With a data set this size it is possible to derive generalizations about the types of mechanisms causing the leanness. A useful first distinction is between mice lacking normal adipocytes and those in which the adipocytes are triglyceride depleted but otherwise intact and functional. The mice with ablated or malfunctioning adipocytes have insulin resistance (and often actual hyperglycemia); enlarged, fatty livers; and elevated circulating triglyceride levels. In contrast, mice with depleted adipocytes typically are insulin sensitive, have normal sized livers, and have normal or low liver and circulating triglycerides.

A number of different mechanisms can cause triglyceride depletion of adipocytes. In theory, significantly increased metabolism anywhere in the body can cause leanness by a “substrate steal,” burning energy that otherwise would be stored in adipose tissue. Some of the best examples of this are transgenic mice with increased muscle oxidation. Adipose tissue can also be a significant contributor to an increased metabolic rate. This can occur in BAT through increased thermogenesis, with secondary triglyceride depletion in WAT. Alternatively, chronic  $\beta$ -adrenergic stimulation of WAT causes more BAT character to the WAT, increasing its metabolic rate. In models of increased peripheral metabolism, food intake is increased, partially compensating for the increased metabolism.

Triglyceride-depleted adipocytes can also result from decreased energy availability originating in peripheral tissues, such as by impaired intestinal absorption. These mice are analogous to underfeeding accomplished by nongenetic means. This group of mice should have a reduced metabolic rate, indicative of CNS detection and an attempt at compensation for the reduced energy intake.

Another class of mechanisms for producing lean mice with triglyceride-depleted adipocytes is via altered CNS regulation. This group is heterogeneous. It might be subdivided on the basis of what the apparent primary effect is, such as decreased food intake (with compensatory decreased energy expenditure), increased energy expenditure (with compensatory increased food intake), or both decreased food intake and increased energy expenditure. A complementary way to subclassify this group is by the changes in hypothalamic neuropeptide levels, looking for changes from the usual patterns. Matching the neuronal and physiologic changes will push our understanding to new levels.

There are also genetic models that do not fit the patterns. These can be the most interesting mice, providing discrepancies to be deciphered for mechanistic

**TABLE 1** Numbers generally are from young adult mice and should be considered approximations for comparison between mice, due to such differences as genetic background, age, sex, and the laboratory doing the work. For insulin, glucose, and triglyceride levels, numbers are listed only when significantly elevated

Gene description	Type of mutation, site of expression	Tissue affected	WAT	BAT	Liver size	Liver triglyceride	Insulin sensitivity	Insulin (ng/ml)	Glucose (mg/dl)	Triglyceride (mg/dl)	Leptin (ng/ml)	Food intake	Physical activity	Metabolic rate	Reference
<b>1. Peripherally driven increased energy expenditure via muscle</b>															
myosin light chain 2 driving UCP1	tg, muscle	muscle	60%				↑	↓	↓	↓		↑	N	↑	(60)
α-skeletal actin driving UCP3	tg, muscle	muscle	50%					↓	↓	N	N	↑	N	↑	(14)
creatine kinase driving LPL	tg, muscle	muscle	↓				var	N, ↑	N, ↑	↓		N, ↑			(43, 59)
<b>2. Peripherally driven increased energy expenditure via adipose tissue</b>															
ap2 driving β1 adrenergic receptor	tg, adipose	fat	75%	N											(93)
ap2 driving UCP1	tg, adipose	fat	var	N	N										(51)
Rilβ subunit of protein kinase A translation inhibitor	ko	fat	50%	N				N	N	N	↓	↑			(17, 79)
4E-BP1	ko	fat	40%	N				N	↓	N	↓			↑	(97)
ap2 driving FOXC2 transcription factor	tg, adipose	fat	20%	4x↑	N	N	↑	↓	↓	↓					(12)
<b>3. Increased energy expenditure via multiple or unknown tissues</b>															
overexpress glycerol 3-P dehydrogenase	tg, wide	multiple	25%	2x↑											(53, 54)
protein tyrosine phosphatase-1B	ko	?liver/muscle	30%	N			↑	↓	↓	↓	↓	N, ↑		↑	(23, 48)



**TABLE 1** (Continued)

Gene description	Type of mutation, site of expression affected	WAT	BAT	Liver size	Liver triglyceride	Insulin sensitivity	Insulin (ng/ml)	Glucose (mg/dl)	Triglyceride (mg/dl)	Leptin (ng/ml)	Food intake activity	Physical Metabolic rate	Reference
<b>6. Special cases</b>													
C/EBP $\beta$	ko	multiple	50%	less lipid		↑	N	N	N				(4, 62, 94, 99)
C/EBP $\delta$	ko	multiple	70%	less lipid									(94)
C/EBP $\beta$ C/EBP $\delta$ double ko	double ko	multiple	30%	less lipid									(94)
HMG1-C	ko, 4 times	?fat	20%								N, ↑		(2, 5, 7 107, 113)
GLUT4 metallothionin driving	ko	fat/muscle	15%										(45, 96)
TGF $\alpha$	tg, wide	?fat/multiple	50%			↓	↑ var	↓ var				N	(64)
keratin driving TNF $\alpha$	tg, skin	?fat/multiple	none visible										(13)
<b>7. Abnormal adipocyte biochemistry</b>													
perilipin	ko	fat	30%	less lipid	N	N	1.2	↑	N	↑	N		(66, 95)
<b>8. WAT ablation</b>													
C/EBP $\alpha$ knockout, with liver C/EBP $\alpha$	ko with tg liver	fat/multiple	var	N	2x↑	↑	5	N	1100	↓			(61)
ap2 driving dominant negative A-ZIP/F	tg, adipose fat	1%		N, fast	2.1x↑	↑	↓	100	600	↓	↑	N	(27–29, 71)
ap2 driving constitutively active SREBP-1c	tg, adipose fat	35%	4x↑	1.8x↑	1.8x↑	↑	↓	20	300	110	↓		(89, 90)
ap2 driving modified diphtheria toxin	tg, adipose fat	10%	reduced @ 10 mo.	3.5x↑	3.5x↑	↑	↓	12	250	120	↑		(9, 84)
PEPCK driving TGF $\beta$ 1	tg, wide	fat/multiple	10%	1/3 of N weight	1.2x↑	↑				170			(15)
lipin-1 (flid and fld2J alleles)	natural mutations	fat	20%	reduced in adult	1.2x↑	↑	4	N		↓			(77, 78, 82)

Key: N, normal; tg, transgene; ko, knockout; var, variable.

insight. Finally, a reduced fat mass can also be a “nonspecific” manifestation of a sick animal. This is not to dismiss the effects of illness on energy hemostasis, but in severely ill mice it is difficult to sort out the specific effects on energy homeostasis (e.g., role of cytokines) from indirect effects (e.g., it hurts to move, so the mouse does not eat). With a possible exception (13), we have not included severely ill mice in this review, unless they provide mechanistic insight.

## EXPERIMENTAL ASSESSMENT OF ALTERED ADIPOSITY AND ITS CAUSES

### Measuring Adiposity

Before examining particular mouse models we review a few points about the measurement and evaluation of adiposity and the phenotyping of mice. The ideal method would allow repeated measurement over time of the same mouse, while providing information about regional fat distribution. Body weight, while an imperfect measurement, is easy to measure accurately and to follow over time in a live mouse. More specific is the body mass index (BMI), weight divided by length squared. In the mouse the nose to anus length is used. Whereas the BMI corrects for differences in body size, it usually requires an anesthetized mouse and the same observer for accurate, reproducible data. A more sensitive and specific measurement of adiposity is fat pad weight. Other techniques used to measure adiposity include carcass triglyceride content, dual energy X-ray absorptiometry, nuclear magnetic resonance spectroscopy, magnetic resonance imaging, and computerized tomography.

### Scaling Measurements to Body Weight

Leanness and obesity result from an imbalance between energy intake and expenditure. Thus, the determinants of fat mass are net energy intake and energy expenditure, with the efficiency of energy expenditure and partitioning of energy to or from fat being important secondary determinants. Small but chronic differences in energy balance, if sustained, have a profound effect on fat stores. Experimentally, food intake is the commonly used measure of net energy intake (the calories lost in urine/feces are often not quantitated, and in most cases this will not significantly affect the conclusions). Energy expenditure in mice is usually measured as oxygen consumption using indirect calorimetry (69).

Energy intake and expenditure vary with body size; thus, it is important to normalize these measurements. Observations by Kleiber revealed an empiric fit to the  $3/4$  power of body weight (49, 50), and a first principles explanation for such “allometric” scaling was proposed. Briefly, the  $3/4$  power results from the constraints of maximally efficient transport (of nutrients and waste) within the body, which presumably has been selected for during evolution (6, 103, 104).

WAT can vary widely in amount (from <2% of body weight in lipoatrophic mice to ~80% in mice lacking leptin). Because WAT consists chiefly of stored, inert triglyceride, which does not contribute to metabolic activity, normalization to (body weight)<sup>3/4</sup> is not appropriate for comparing animals with different percentages of body fat. Ideally, the most accurate normalization is to (lean body mass)<sup>3/4</sup>. For groups of animals with the same fat mass and body weight, normalization is not required but tends to reduce the error.

## Importance of Ambient Temperature in Smaller Mammals

Thermoregulation is profoundly different in homeotherms (warm-blooded animals) with small bodies and those with large bodies. Heat loss is rapid in small animals, owing to their high surface area:volume ratio, and consequently they normally burn calories to keep warm (called facultative thermogenesis). Small mammals also compensate for heat loss by behavioral adaptation (nesting, huddling). In contrast, maintaining body temperature is relatively easy for adult humans, who rely predominantly on behavioral adaptation (clothes, creating a warm environment) and not thermogenesis for keeping warm.

The thermoneutral zone, defined as the range of ambient temperatures at which the metabolic rate is at a minimum (30), is broad for adult humans, extending from ~24° to >37°C (86, 105) (Figure 1). Indeed, decreasing the ambient temperature from 28° to 22°C increases the metabolic rate by only 7% (19). The thermoneutral zone in mice is ~30–34°C (30, 37), and mice show huge increases in metabolic rate at environmental temperatures below thermoneutrality [22°C causes an increase of 80% and 4°C, an increase of 320% (35)]. The ability of mice to profoundly increase metabolic rate can have major effects. For example, the difference of a few degrees in ambient temperature measurably changes food intake and metabolic rate. Experimentally this can be addressed by measurement of food intake and metabolic rate at thermoneutrality.

From the facts discussed above, it follows that body temperature is not a surrogate measure of metabolic rate. Figure 1 illustrates this lack of correlation between metabolic rate and body temperature.


## Effects of Sex, Age, Diet, and Background Genotype

There are differences, sometimes profound, between male and female mice in leanness/obesity and diabetes phenotypes. Leanness/obesity can be more significant in one sex (75). Insulin resistance/diabetes phenotypes are often worse in male mice (58).

As mice age they generally become more obese. There are transgenic mice that exaggerate this process (80) but also mice that do the opposite (9). The probability of diabetes generally increases with age, but in some models hyperglycemia improves with age (16, 58).

Diet has a major effect on leanness and insulin resistance. Typical rodent chow has 12% of calories as fat. Increasing the fat content increases the probability





**Figure 1** Metabolic rate and body temperature (Tb) as a function of ambient temperature. The dotted line marks room temperature, showing the small increase in human and the large increase in mouse metabolic rate, compared with thermoneutrality. Data are from the following sources: human metabolic rate (*dashed line*) (40), mouse metabolic rate (*solid line*) (35, 37), and mouse body temperature (39).

of obesity and insulin resistance. This is one of the common ways to check for resistance to obesity in mouse models. The type of dietary carbohydrate is also important. For example, high fructose diets are more diabetogenic.

Another important influence is background genotype. Huge effects have been reported on body fat content and response to a high fat diet (102). Different inbred strains can show a 130-fold variation in WAT uncoupling protein-1 (UCP1) mRNA levels (31). Background genotype can mean the difference between normal glucose levels and diabetes. Thus, mice should be on a pure genetic background or compared with littermate controls.

## SPECIFIC EXAMPLES OF GENETICALLY LEAN MICE

### Peripherally Driven Increased Energy Expenditure via Muscle

Two groups have produced lean transgenic mice with increased energy expenditure in muscle owing to uncoupling proteins. Li et al. expressed UCP1 in skeletal muscle (60). UCP1 is normally found only in BAT and uncouples substrate oxidation from ADP phosphorylation by causing the mitochondrial inner membrane to become

leaky to protons. Clapham et al. overexpressed a related protein, UCP3, in muscle (14), although the increased leak was apparently not due to normal functioning of the UCP3 protein (10). In both models body weight was reduced, as was the fraction of body weight that is fat. Whole body and isolated muscle metabolic rates increased. These data suggest that the UCP transgenes increased muscle proton leak, causing a secondary increase in substrate oxidation in order to maintain ATP levels. The mice increased their food intake to replenish their energy stores, but this did not completely compensate, leading to thinner, leaner mice. Both models show increased whole body insulin sensitivity.

These mice are the clearest examples of transgenic mice that become lean by a primary increase in energy expenditure. Like nongenetic models of leanness, such as caloric restriction or increased exercise, these mice show increased insulin sensitivity. It is interesting to note that the UCP1-overexpressing mice had a small but significant increase in muscle triglyceride (60), similar to endurance-trained humans (76). These provocative experiments raise a number of questions. Does increased uncoupling in muscle have antidiabetic effects above and beyond those caused by decreased fat mass? Would increased uncoupling in liver have the same effect? What about increased uncoupling in a tissue that is not insulin responsive? Are there untoward effects caused by chronically elevated uncoupling?

Mice expressing lipoprotein lipase (LPL) in muscle become lean in proportion to the degree of overexpression (59). This occurs despite normal (increased for body size) food intake, indicating that the increased delivery of fatty acid to muscle must stimulate metabolism in some way. Lower levels of muscle LPL expression cause resistance to dietary or genetic (*ob/ob*) obesity but not leanness in the absence of such a stress (43,101). However, these low levels of muscle LPL do cause isolated muscle insulin resistance (46). A likely explanation is that increased intracellular fatty acids or their metabolites contribute to insulin resistance. As might be predicted, LPL deletion is a lethal phenotype, with the mice being unable to deposit triglyceride into their WAT before they die (100).

## Peripherally Driven Increased Energy Expenditure via Adipose Tissue

The major stimulus for heat production by BAT and lipolysis in WAT is  $\beta$ -adrenergic stimulation via the sympathetic nervous system. In BAT, this signals via protein kinase A and PPAR $\gamma$  coactivator-1 (PGC1) to increase Ucp1 levels and activate uncoupling. The mouse models in this section have in common activation of this pathway, albeit by different methods and at different sites.

Mice overexpressing the  $\beta$ 1-adrenergic receptor in adipose tissue had smaller adipose tissue depots, showed an increased lipolytic response to  $\beta$ -adrenergic stimulation, and had brown fat cells appearing in traditionally white adipose depots (93). These changes mimic those seen in mice chronically cold-challenged or treated with a  $\beta$ 3-adrenergic agonist. Because lean mice and mice treated with

a  $\beta 3$  agonist are more insulin sensitive, the  $\beta 1$  overexpressors may be insulin sensitive, although this was not reported.

Transgenic mice expressing Ucp1 in adipose tissue were resistant to obesity caused either by ectopic agouti expression ( $A^y$ ) or a high fat diet (51, 52). Interestingly, the change in fat pad weights was gender dimorphic and region specific (reduced femoral and mesenteric WAT, no change in renal WAT, and an increase in male gonadal WAT) (51). The presumed mechanism in these mice is the excess energy expenditure by the Ucp1 transgene in white and brown adipose tissue.

The lean phenotype resulting from disruption of the  $RII\beta$  subunit of protein kinase A was quite unexpected (17). This gene is most abundantly expressed in adipose tissue and brain. In compensation for  $RII\beta$  ablation, the mouse upregulates the  $RI\alpha$  isoform. Protein kinase A holoenzyme containing  $RI\alpha$  is activated at lower cAMP levels, leading to a higher adipose tissue protein kinase A activity in response to  $\beta$ -adrenergic stimulation (17, 79). The result is a lean phenotype owing to increased WAT lipolysis and BAT thermogenesis. In this mouse one must remember that  $RII\beta$  is also expressed in the brain, and ablation has behavioral effects (8).

Translation inhibitor 4E-BP1 is expressed at high levels in multiple tissues, including WAT, BAT, and pancreatic islets. Phosphorylation of 4E-BP1 disinhibits translation and occurs in response to treatment of adipocytes with insulin. Mice lacking translation inhibitor 4E-BP1 (*Eif4bp1* $^{-/-}$ ) were lean and hypoglycemic (97). The *Eif4bp1* $^{-/-}$  WAT had BAT-like characteristics presumably owing to increased PGC-1 translation, leading to increased Ucp1, BAT histology, and increased energy expenditure.

In adult mice the *Foxc2* is a transcription factor that is expressed selectively in adipose tissue. *Foxc2* $^{-/-}$  mice fail to live past the neonatal period (41, 106); the WAT phenotype of *Foxc2* $^{+/-}$  mice has not been reported. Transgenic FOXC2 overexpression in adipose tissue produced lean, insulin-sensitive mice with BAT hypertrophy (12). The WAT in these mice expressed Ucp1, consistent with a partially BAT-like histology. These results suggest that transgenic adipose overexpression of FOXC2 causes a lean phenotype through increased adipose tissue energy expenditure. The role of *Foxc2* in the regulation of normal adipose tissue remains to be examined.

### Increased Energy Expenditure via Multiple or Unknown Tissues

Mice overexpressing cytoplasmic glycerol 3-phosphate dehydrogenase are lean (54). When bred to *db/db* mice, the transgene reduced the body weight to wild-type levels (53). The likely explanation is that these mice have increased basal metabolism and heat production. Specifically, cytoplasmic and mitochondrial glycerol 3-phosphate dehydrogenases together constitute the glycerol phosphate shuttle, an energetically inefficient (and thus heat-producing) way to move reducing equivalents from the cytoplasm into the mitochondrion [reviewed in (20)]. Consistent with this hypothesis is the observation that the BAT, although capable of

activating in response to cold, was inactive, suggesting that it was dormant, compensating for increased heat production elsewhere (54). Insulin sensitivity has not been measured in these mice, but they are predicted to be more sensitive.

Mice lacking acetyl-CoA carboxylase 2 (*Acc2*<sup>-/-</sup>) are lean (1). The reduction in muscle and heart acetyl-CoA carboxylase activity causes a decrease in malonyl CoA, activating carnitine palmitoyl transferase-1 and thus increasing fatty acid oxidation. The increased muscle fatty acid oxidation and metabolic rate result in less triglyceride in adipose tissue and liver and an increase in food intake in an attempt to compensate (1). Alternatively, one cannot rule out a CNS effect from the loss of neuronal *Acc2*.

Ablation of the protein tyrosine phosphatase-1B gene results in increased or prolonged insulin receptor phosphorylation in liver and muscle but not in adipose tissue (23). These mice have lower blood glucose, insulin, and triglyceride levels and are more insulin sensitive in muscle but not adipose tissue (23, 48). The mice have normal or increased food intake despite being obesity resistant; this is explained by an increased metabolic rate (48). The knockout phenotype may be explained by augmented insulin action in liver, muscle, and/or CNS causing increased substrate oxidation, making less available for storage in WAT. Another possible mechanism is increased phosphorylation of insulin-independent pathways.

Mice lacking complement C3 are immune deficient and lean (72). Because they are lean despite increased food intake, the mice must be hypermetabolic, but the involved tissues are not known. A possible mechanism for the phenotype is the deficiency of C3adesArg, also known as acylation-stimulating protein, which is proposed to regulate fatty acid uptake in adipocytes (92).

A mouse with a lean phenotype was observed with paternal transmission (+/p-) of the *G<sub>s</sub>α* knockout allele (111). *G<sub>s</sub>α* is the stimulatory  $\alpha$  subunit, via which G-protein-coupled receptors increase cAMP. The *Gnas* gene is imprinted in a tissue-specific manner, meaning that in certain tissues only one parental allele is expressed (112). Uncovering the primary event in the +/p- mice responsible for their leanness is difficult because there are hundreds of G-protein-coupled receptors. A working model is that cAMP signaling from certain G-protein-coupled receptors is impaired. This causes increased sympathetic tone to WAT and BAT, an increased resting metabolic rate, and increased physical activity (111). Food intake is also increased, possibly secondary to the increased energy expenditure. Insulin sensitivity in the +/p- mice is increased (110).

An intriguing lean, insulin sensitive mouse resulted from ablation of the acyl-CoA:diacylglycerol transferase (DGAT) gene, which encodes the enzyme that converts diacylglycerol to triglyceride. Initially, it was surprising that *Dgat1* knockout mice have normal circulating triglyceride levels (91), but further investigations identified additional DGAT genes (11). In the *Dgat1* knockout mice, fat pad weights were reduced by 60–80%, and carcass triglycerides were reduced by 33%. Glucose tolerance results suggested increased insulin sensitivity. The lean phenotype appeared to result from increased physical activity and metabolic rate and not decreased food intake. It is not known how ablation of the *Dgat1* gene causes the lean phenotype, not even which tissue is the primary site (adipose, brain, other).

It is tempting to speculate that *Dgat1* ablation causes abnormal CNS sensing of energy stores, for example by analogy to the lean phenotype caused by inhibition of fatty acid synthase (63).

## Central Nervous System–Mediated Lean Mice

Some lean transgenic mice have an altered energy homeostasis causing them to act physiologically as if they have ample or excessive energy stores when this is not the case. The hallmark of CNS regulation is that multiple mechanisms are involved, such as decreasing food intake and increasing physical activity and other forms of energy expenditure. However, some alterations of CNS regulation affect only some of the inputs to energy homeostasis.

One way to affect all of the CNS regulation is to increase the circulating leptin levels. Most investigators have done this with injections or short-term continuous infusions. Transgenic expression allows longer treatments and higher doses. Mice secreting leptin from adipose tissue (42, 80) and liver (67, 74) have been produced.

The transgenic mice with the highest leptin levels (~10 times higher than littermates and ~100 times higher than expected for the degree of fat mass) were lean with no visible WAT and decreased food intake (74). The mice had decreased circulating and hepatic triglyceride levels and increased insulin sensitivity. Based on known effects of leptin, it is likely that these mice were also less metabolically efficient and expended more energy. Interestingly, one of the leptin-overexpressing models with a low adipose mass at 6–9 weeks of age had normal adipose stores at 33–36 weeks, despite continued elevation of leptin levels (80).

Downstream of leptin are the proopiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus. These POMC neurons secrete  $\alpha$ -melanocyte stimulating hormone ( $\alpha$ MSH), an agonist of melanocortin-3 and melanocortin-4 receptors. The melanocortin pathway is anorexigenic; thus, activators of this pathway should produce lean mice. To date, no transgenic mice that directly activate this pathway have been reported.  $\alpha$ MSH action is inhibited by agouti-related protein (Agrp); an Agrp knockout is also predicted to be lean (21).

The *mahogany* mutations were identified as lessening the effects of ectopic *agouti* expression in *A<sup>y/a</sup>* mice. It is now known that the *mahogany* mutations are in the attractin gene and range from null to hypofunctional alleles (33, 73). The attractin protein binds and inhibits the action of agouti, but not of Agrp, thus this mechanism for attractin's effect on energy homeostasis is restricted to models that ectopically express agouti protein (36). However, attractin has also been shown to reduce adiposity and increase physical activity in the absence of ectopic agouti expression (22, 32). These effects of attractin mutations are likely due to other, less specific CNS effects, because attractin mutations also cause hypomyelination and neuronal degeneration (55). The *mahoganoid* (*md*) mutation also suppresses *A<sup>y</sup>* obesity (70). However, the molecular basis for the *md* mutation and whether it acts specifically on AGRP are unknown.

Melanin concentrating hormone (MCH) is a neuropeptide acting in the lateral hypothalamus that increases food consumption (81). It is also downstream of

leptin. Knockout mice lacking MCH are lean owing to both decreased food intake and increased metabolic rate (88). These occurred despite reduced circulating leptin levels and arcuate nucleus POMC mRNA levels, confirming that MCH acts downstream of leptin and  $\alpha$ MSH signaling. Glucose and insulin levels were slightly (but not statistically significantly) reduced in the MCH knockout mice, suggesting that these mice tend towards insulin sensitivity.

NPY was one of the first orexigenic neuropeptides identified, and central delivery of NPY remains one of the most potent orexigenic stimuli known. Thus, when NPY $-/-$  mice were generated it was surprising that they were of normal weight and food intake, including hyperphagia following food deprivation (24). Some subtle changes in energy homeostasis in the NPY $-/-$  mice were identified, including augmented decrease in food intake following treatment with leptin (24). When mice doubly ablated for NPY and leptin were studied they showed less obesity, less food intake, and greater energy expenditure than singly leptin deficient mice (25). Possible explanations for the modest phenotype of the NPY $-/-$  mice include redundancy in the energy homeostasis pathways and plasticity during development in the absence of NPY.

Hypothalamic neurons have both Y1 and Y5 NPY receptors, and mice lacking either of these receptors have been produced. Although both mutants show slightly decreased food intake in response to intracerebro-ventricular administration of NPY agonists, both also became obese (65, 75). These data suggest that NPY, acting via the Y1 and Y5 receptors (and possibly others), does affect food intake. However, compensatory changes in energy homeostasis (either directly via Y1 and Y5 receptors or indirectly) also occur, leading to increased adiposity.

A lean phenotype was observed in mice lacking the M3 muscarinic receptor (68, 108). The mechanism appears to decrease food intake owing to altered hypothalamic regulation (108). Hypothalamic AGRP mRNA levels were increased, while POMC ( $\alpha$ MSH) mRNA levels were reduced, consistent with the low body energy stores. In contrast, hypothalamic MCH mRNA levels were reduced, which is not seen in lean mice. Central infusion of AGRP<sub>83-132</sub>, a melanocortin antagonist, did not increase food intake, but MCH did. These data suggest an M3R effect downstream of  $\alpha$ MSH/AGRP and upstream of MCH.

VGF is a secreted neuropeptide whose hypothalamic mRNA levels are induced by fasting. VGF-ablated mice have a remarkably severe phenotype consisting of leanness with increased activity and metabolic rate (34). Hypothalamic mRNA levels of NPY and AGRP were increased and POMC was decreased, consistent with a fasting situation and suggesting that VGF ablation affects pathways downstream of these neurotransmitters.

## Peripherally Decreased Energy Availability

A lean, insulin-sensitive phenotype should result from genetic manipulations to decrease energy intake, analogous to a hypocaloric diet. Decreased food intake could result from decreased appetite, as part of a changed CNS energy store set point (discussed above). Genetic manipulation of gastrointestinal communication

to the brain might include increasing oleylethanolamide signaling (83). Mice overexpressing pancreatic polypeptide weigh less and have less food intake and decreased gastric emptying (98), and thus are possibly a genetic model for decreased food intake. Decreased intake could also result from poor gastrointestinal absorption. One would predict that (partial) loss of pancreatic lipase would result in such a mouse, mimicking the action of orlistat, a lipase inhibitor used clinically (3). Deficiency of intestinal apoB prevents triglyceride uptake by lack of chylomicron formation, leading to profound leanness (44, 109). It is interesting that mice lacking the VLDL receptor have 50% reduced fat mass, presumably owing to decreased triglyceride transport to muscle and adipose tissue (26). No differences in glucose or insulin levels were noted.

### Special Cases: Confusing or Insufficient Information

Both the C/EBP $\beta$  and C/EBP $\delta$  transcription factors, while widely expressed, have been implicated in adipocyte development. Many C/EBP $\beta$ —/— mice die perinatally and the rest are lean (94), with low liver glycogen levels, fasting hypoglycemia, impaired hepatic glucose production, impaired adipocyte lipolysis, and increased muscle insulin sensitivity (4, 62, 99). Thus, the phenotype seems to be determined by the paucity of available energy in the mice. Mice lacking C/EBP $\beta$  selectively in adipose tissue will be required to determine the relative contribution of liver, adipose, and other tissues in causing the phenotype.

C/EBP $\delta$ —/— mice are lean, but the WAT and metabolic phenotypes have not been studied in detail (94). C/EBP $\beta$ —/—C/EBP $\delta$ —/— double knockout mice are leaner than either the C/EBP $\beta$ —/— or C/EBP $\delta$ —/— mice and many die early (94). The uncertainty noted for the individual C/EBP $\beta$ —/— or C/EBP $\delta$ —/— mice also applies to the C/EBP $\beta$ —/—C/EBP $\delta$ —/— mice.

HMGIC is an “architectural” transcription factor, inactivation of which causes the *pygmy* phenotype (5, 7, 107, 113). Pygmy mice are proportionately small, with disproportionately greater fat loss. HMGIC is expressed in proliferating mesenchymal cells and not in most adult tissues, with adipose tissue undergoing expansion being one exception. Thus, the *Hmgic*—/— mice are proposed to be resistant to adipose tissue cell division but not hypertrophy (2).

Ablation of GLUT4, the insulin-sensitive glucose transporter, produced very lean mice, presumably owing to the diminished ability of the WAT to take up glucose (45). The mice were resistant to insulin’s hypoglycemic effect, which was remedied by transgenic replacement of muscle GLUT4 (96).

Mice overexpressing TGF $\alpha$  have a complex phenotype that includes reduced fat depots with normal food intake (64). When crossed with *ob/ob* mice, the *ob/ob* obesity was only slightly reduced. TGF $\alpha$  repressed adipose differentiation in cell culture, but the mechanism for its induction of lean mice is unknown.

### Abnormal Adipocyte Biochemistry

Perilipin is a protein that coats the adipocyte lipid droplets and modulates hormone-sensitive lipase activity. Perilipin knockout mice have increased basal lipolysis

(66, 95). Anatomically they have a reduced adipose mass and an increased muscle mass. Metabolic rate per unit body weight is increased, owing, at least in part, to the increased muscle mass. It is not clear how increased lipolysis would cause increased muscle size; possibly an augmented fatty acid supply causes growth either via a nutritive or hormonal mechanism. Another potential contribution to an increased metabolic rate could be a futile cycle of lipolysis and re-esterification. In virtually all lean mice the circulating leptin levels are reduced in proportion to the degree of fat loss (and thus leptin usually is not particularly useful for characterizing lean mice). The *peri*<sup>-/-</sup> mouse also produces leptin in proportion to fat mass, but at an approximately fivefold greater level. Maybe the *peri*<sup>-/-</sup> mouse holds the answer to how increased adipocyte triglyceride causes increased leptin transcription.

## White Adipose Tissue Ablation

Multiple mouse models involving ablation of WAT have been reported. As noted above, characteristics of all WAT-ablated mice include insulin resistance, fatty liver, and increased circulating triglyceride levels.

C/EBP $\alpha$  is a transcription factor important for the expression of many adipocyte genes. *c/ebp $\alpha$* <sup>-/-</sup> mice die within hours of birth with hypoglycemia, owing to defective gluconeogenesis (18). The adipose tissue in the *c/ebp $\alpha$* <sup>-/-</sup> mice failed to accumulate lipid, but this was difficult to interpret owing to the other affected tissues. Thus, the role of adipocyte C/EBP $\alpha$  was investigated using transgenic hepatic C/EBP $\alpha$  expression in the *c/ebp $\alpha$* <sup>-/-</sup> mice (61). The resulting mice had near-normal BAT and mammary WAT but absence of subcutaneous, perirenal, and epididymal WAT. Furthermore, the mice had high triglyceride levels and fatty liver, along with high insulin levels, suggesting insulin resistance. Despite the effects of C/EBP $\alpha$  deficiency in other tissues, these data suggest that the lack of adipose C/EBP $\alpha$  causes the observed phenotype and raises the possibility that C/EBP $\alpha$  is not important for BAT development and function.

Three groups used the aP2/422 adipose fatty acid binding protein promoter/enhancer to drive transgene expression selectively in adipose tissue. The first group to make WAT-ablated transgenic mice used expression of a modified diphtheria toxin to produce the aP2-DT-A mice (84). They observed different phenotypes. Offspring of certain mosaic founders died soon after birth with chylous ascites, presumably owing to transgene expression levels that were not compatible with life. A strain expressing much less DT-A transgene initially appeared normal. However, at >6 months of age these mice showed decreased fat mass and were insulin resistant (9). This strain was also resistant to hypothalamic obesity produced by monosodium glutamate injection into newborns.

The most severe viable adipose deficiency model is the A-ZIP/F-1 transgenic mouse. The transgene is a dominant negative protein that heterodimerizes with and inactivates members of the C/EBP and JUN families of B-ZIP transcription factors (71). Features of the model include virtually no visible WAT at any time during development but near normal BAT at birth, which undergoes accelerated,



premature involution, becoming reduced in amount and inactive. The livers of the A-ZIP/F-1 mice are enlarged and engorged with lipid, but show little hepatitis. The mice have elevated serum free fatty acids and triglycerides and reduced leptin levels. The A-ZIP/F-1 mice are severely diabetic, with remarkably elevated (50- to 400-fold) insulin levels (71). Both the muscle and liver are severely insulin resistant, even before the onset of overt hyperglycemia at 4 weeks of age (47). The  $\beta$ -cell number of the pancreatic islets is increased, particularly in older mice.

The third WAT-ablated transgenic mouse expresses a constitutively active form of the SREBP-1c transcription factor (90). The WAT-deficient phenotype of the aP2-nSREBP-1c mice was a surprise because SREBP-1c is thought to stimulate lipogenesis. The phenotype of the aP2-nSREBP-1c mice is slightly less severe than that of the A-ZIP/F-1 mice, with a reduction in WAT mass of  $\sim 70\%$ . They also have hepatomegaly and hepatic steatosis without hepatitis and elevated blood triglyceride and low leptin levels. aP2-nSREBP-1c mice have insulin resistance with hyperglycemia and hyperinsulinemia (90). Sufficient WAT was present to allow characterization of its gene expression profile. The WAT showed increased expression of Pref-1, a marker of preadipocytes, and decreased expression of genes characteristic of fully differentiated adipocytes (PPAR $\gamma$ , C/EBP $\alpha$ , adipsin, aP2, and leptin).

The BAT of the aP2-nSREBP-1c mice was larger, whiter, and contained more lipid droplets than did control BAT. The BAT showed increased Pref-1 expression and decreased PPAR $\gamma$ , C/EBP $\alpha$ , adipsin, aP2, and UCP1 expression. The enlarged, immature BAT phenotype of the aP2-nSREBP-1c mice is different from the premature involution phenotype of the A-ZIP/F-1 mice. These differences presumably reflect the underlying transgene effects.

The fatty liver dystrophy (*fld/fld*, now formally, *lpin1<sup>fld</sup>/lpin1<sup>fld</sup>*) mouse is a spontaneously arising model of WAT deficiency. The phenotype of the *fld/fld* mouse includes fatty liver and hypertriglyceridemia, which both resolve by weaning, and a peripheral neuropathy that does not (56, 57). The *fld/fld* mice have 50–90% reductions in WAT and BAT mass (in young and old mice) and mild insulin resistance (a two- to fourfold increase in insulin levels) without hyperglycemia (82). Recently, causative mutations were identified in the *Lpin1* gene encoding lipin (78). Lipin is expressed at highest levels in differentiated adipose tissue, testis, and muscle and at lower levels in other tissues, including liver. Lipin is an 891-amino acid nuclear protein of unknown function. The insulin resistance of the *fld/fld* mouse may result from the WAT deficiency, but this has not been confirmed experimentally. The causal relationships between the various abnormalities in the *fld/fld* mouse are unclear.

## CONCLUSIONS

By classifying the reported lean mouse models, some general principles have become clear. Most obvious is the distinction between adipose tissue ablation and low adipose triglyceride stores. All of the mice discussed in this review were

reported in the past 10 years. Whereas an infinite percentage increase in the number of lean mice cannot occur in the next decade, the future still holds much promise for the study of genetically lean mice. They should continue to teach us the peripheral and CNS pathways, mechanisms, and physiology of energy homeostasis.

## ACKNOWLEDGMENT

I thank Dr. Oksana Gavrilova and the members of my laboratory for stimulating discussion and sage advice during the writing of this review.

**The Annual Review of Nutrition is online at <http://nutr.annualreviews.org>**

## LITERATURE CITED

1. Abu-Elheiga L, Matzuk MM, Abo-Hashema KA, Wakil SJ. 2001. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. *Science* 291:2613–16
2. Anand A, Chada K. 2000. In vivo modulation of Hmgic reduces obesity. *Nat. Genet.* 24:377–80
3. Anonymous. 1999. Orlistat for obesity. *Med. Lett. Drugs Ther.* 41:55–56
4. Arizmendi C, Liu S, Croniger C, Poli V, Friedman JE. 1999. The transcription factor CCAAT/enhancer-binding protein beta regulates gluconeogenesis and phosphoenolpyruvate carboxykinase (GTP) gene transcription during diabetes. *J. Biol. Chem.* 274:13033–40
5. Ashar HR, Fejzo MS, Tkachenko A, Zhou X, Fletcher JA, et al. 1995. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. *Cell* 82:57–65
6. Banavar JR, Maritan A, Rinaldo A. 1999. Size and form in efficient transportation networks. *Nature* 399:130–32
7. Benson KF, Chada K. 1994. Mini-mouse: phenotypic characterization of a transgenic insertional mutant allelic to pygmy. *Genet. Res.* 64:27–33
8. Brandon EP, Logue SF, Adams MR, Qi M, Sullivan SP, et al. 1998. Defective motor behavior and neural gene expression in RIIbeta-protein kinase A mutant mice. *J. Neurosci.* 18:3639–49
9. Burant CF, Sreenan S, Hirano K, Tai TA, Lohmiller J, et al. 1997. Troglitazone action is independent of adipose tissue. *J. Clin. Invest.* 100:2900–8
10. Cadenas S, Echtaay KS, Harper JA, Jekabsons MB, Buckingham JA, et al. 2002. The basal proton conductance of skeletal muscle mitochondria from transgenic mice overexpressing or lacking uncoupling protein-3. *J. Biol. Chem.* 277:2773–78
11. Cases S, Stone SJ, Zhou P, Yen E, Tow B, et al. 2001. Cloning of dgat2, a second mammalian diacylglycerol acyltransferase, and related family members. *J. Biol. Chem.* 276:38870–76
12. Cederberg A, Gronning LM, Ahren B, Tasken K, Carlsson P, Enerback S. 2001. FOXC2 is a winged helix gene that counteracts obesity, hypertriglyceridemia, and diet-induced insulin resistance. *Cell* 106:563–73
13. Cheng J, Turksen K, Yu QC, Schreiber H, Teng M, Fuchs E. 1992. Cachexia and graft-vs.-host-disease-type skin changes in keratin promoter-driven TNF alpha transgenic mice. *Genes Dev.* 6:1444–56
14. Clapham JC, Arch JR, Chapman H, Haynes A, Lister C, et al. 2000. Mice overexpressing human uncoupling protein-3

- in skeletal muscle are hyperphagic and lean. *Nature* 406:415–18
15. Clouthier DE, Comerford SA, Hammer RE. 1997. Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice. *J. Clin. Invest.* 100:2697–713
  16. Coleman DL, Hummel KP. 1973. The influence of genetic background on the expression of the obese (Ob) gene in the mouse. *Diabetologia* 9:287–93
  17. Cummings DE, Brandon EP, Planas JV, Motamed K, Idzerda RL, McKnight GS. 1996. Genetically lean mice result from targeted disruption of the RII beta subunit of protein kinase A. *Nature* 382:622–26
  18. Darlington GJ, Wang N, Hanson RW. 1995. C/EBP alpha: a critical regulator of genes governing integrative metabolic processes. *Curr. Opin. Genet. Dev.* 5:565–70
  19. Dauncey MJ. 1981. Influence of mild cold on 24 h energy expenditure, resting metabolism and diet-induced thermogenesis. *Br. J. Nutr.* 45:257–67
  20. Dawson AG. 1979. Oxidation of cytosolic NADH formed during aerobic metabolism in mammalian cells. *Trends Biochem. Sci.* 4:171–76
  21. Dinulescu DM, Cone RD. 2000. Agouti and agouti-related protein: analogies and contrasts. *J. Biol. Chem.* 275:6695–98
  22. Dinulescu DM, Fan W, Boston BA, McCall K, Lamoreux ML, et al. 1998. Mahogany (mg) stimulates feeding and increases basal metabolic rate independent of its suppression of agouti. *Proc. Natl. Acad. Sci. USA* 95:12707–12
  23. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, et al. 1999. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. *Science* 283:1544–48
  24. Erickson JC, Clegg KE, Palmiter RD. 1996. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. *Nature* 381:415–21
  25. Erickson JC, Hollopeter G, Palmiter RD. 1996. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. *Science* 274:1704–7
  26. Frykman PK, Brown MS, Yamamoto T, Goldstein JL, Herz J. 1995. Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor. *Proc. Natl. Acad. Sci. USA* 92:8453–57
  27. Gavrilova O, Leon LR, Marcus-Samuels B, Mason MM, Castle AL, et al. 1999. Torpor in mice is induced by both leptin-dependent and -independent mechanisms. *Proc. Natl. Acad. Sci. USA* 96:14623–28
  28. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, et al. 2000. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. *J. Clin. Invest.* 105:271–78
  29. Gavrilova O, Marcus-Samuels B, Leon LR, Vinson C, Reitman ML. 2000. Leptin and diabetes in lipoatrophic mice. *Nature* 403:850
  30. Gordon CJ. 1993. Metabolic thermoneutral zone. In *Temperature Regulation in Laboratory Rodents*, pp. 62–66. New York: Cambridge Univ. Press
  31. Guerra C, Koza RA, Yamashita H, Walsh K, Kozak LP. 1998. Emergence of brown adipocytes in white fat in mice is under genetic control. Effects on body weight and adiposity. *J. Clin. Invest.* 102:412–20
  32. Gunn TM, Inui T, Kitada K, Ito S, Wakamatsu K, et al. 2001. Molecular and phenotypic analysis of attractin mutant mice. *Genetics* 158:1683–95
  33. Gunn TM, Miller KA, He L, Hyman RW, Davis RW, et al. 1999. The mouse mahogany locus encodes a transmembrane form of human attractin. *Nature* 398:152–56
  34. Hahm S, Mizuno TM, Wu TJ, Wisor JP, Priest CA, et al. 1999. Targeted deletion of the Vgf gene indicates that the encoded secretory peptide precursor plays a novel

- role in the regulation of energy balance. *Neuron* 23:537–48
35. Hart JS. 1950. Interrelations of daily metabolic cycle, activity and environmental temperature of mice. *Can. J. Res.* 28D:293–307
36. He L, Gunn TM, Bouley DM, Lu XY, Watson SJ, et al. 2001. A biochemical function for attractin in agouti-induced pigmentation and obesity. *Nat. Genet.* 27:40–47
37. Herrington LP. 1940. The heat regulation of small laboratory animals at various environmental temperatures. *Am. J. Physiol.* 129:123–39
38. Hollopeter G, Erickson JC, Palmiter RD. 1998. Role of neuropeptide Y in diet-, chemical- and genetic-induced obesity of mice. *Int. J. Obes. Relat. Metab. Disord.* 22:506–12
39. Hudson JW, Scott IM. 1979. Daily torpor in the laboratory mouse, *mus musculus* var. albino. *Physl. Zool.* 52:205–18
40. Iampietro PF, Vaughan JA, Goldman RF, Kreider MB, Masucci F, Bass DE. 1960. Heat production from shivering. *J. Appl. Physiol.* 15:632–34
41. Iida K, Koseki H, Kakinuma H, Kato N, Mizutani-Koseki Y, et al. 1997. Essential roles of the winged helix transcription factor MFH-1 in aortic arch patterning and skeletogenesis. *Development* 124:4627–38
42. Ioffe E, Moon B, Connolly E, Friedman JM. 1998. Abnormal regulation of the leptin gene in the pathogenesis of obesity. *Proc. Natl. Acad. Sci. USA* 95:11852–57
43. Jensen DR, Schlaepfer IR, Morin CL, Pennington DS, Marcell T, et al. 1997. Prevention of diet-induced obesity in transgenic mice overexpressing skeletal muscle lipoprotein lipase. *Am. J. Physiol. Regulatory Integrative Comp. Physiol.* 273:R683–R89
44. Jung HR, Turner SM, Neese RA, Young SG, Hellerstein MK. 1999. Metabolic adaptations to dietary fat malabsorption in chylomicron-deficient mice. *Biochem. J.* 343(Pt 2):473–78
45. Katz EB, Stenbit AE, Hatton K, DePinho R, Charron MJ. 1995. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. *Nature* 377:151–55
46. Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, et al. 2001. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. *Proc. Natl. Acad. Sci. USA* 98:7522–27
47. Kim JK, Gavrilova O, Chen Y, Reitman ML, Shulman GI. 2000. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. *J. Biol. Chem.* 275:8456–60
48. Klamann LD, Boss O, Peroni OD, Kim JK, Martino JL, et al. 2000. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. *Mol. Cell. Biol.* 20:5479–89
49. Kleiber M. 1932. Body size and animal metabolism. *Hilgardia* 6:315–53
50. Kleiber M. 1975. Body size and metabolic rate. In *The Fire of Life*, pp. 179–222. Huntington, NY: Krieger
51. Kopecky J, Clarke G, Enerback S, Spiegelman B, Kozak LP. 1995. Expression of the mitochondrial uncoupling protein gene from the aP2 gene promoter prevents genetic obesity. *J. Clin. Invest.* 96:2914–23
52. Kopecky J, Hodny Z, Rossmeisl M, Syrový I, Kozak LP. 1996. Reduction of dietary obesity in aP2-Ucp transgenic mice: physiology and adipose tissue distribution. *Am. J. Physiol. Endocrinol. Metab.* 270:E768–E75
53. Kozak LP, Kozak U, Clarke G, Enerback S, Kopecky J. 1996. Genes of energy balance: modulation in transgenic mice. In *Molecular and Genetic Aspects of Obesity*, ed. GA Bray, DA Ryan, pp. 609–23. Baton Rouge: Louisiana State Univ. Press
54. Kozak LP, Kozak UC, Clarke GT. 1991.

- Abnormal brown and white fat development in transgenic mice overexpressing glycerol 3-phosphate dehydrogenase. *Genes Dev.* 5:2256–64
55. Kuramoto T, Kitada K, Inui T, Sasaki Y, Ito K, et al. 2001. Attractin/mahogany/zitter plays a critical role in myelination of the central nervous system. *Proc. Natl. Acad. Sci. USA* 98:559–64
56. Langner CA, Birkenmeier EH, Ben-Zeev O, Schotz MC, Sweet HO, et al. 1989. The fatty liver dystrophy (fld) mutation. A new mutant mouse with a developmental abnormality in triglyceride metabolism and associated tissue-specific defects in lipoprotein lipase and hepatic lipase activities. *J. Biol. Chem.* 264:7994–8003
57. Langner CA, Birkenmeier EH, Roth KA, Bronson RT, Gordon JI. 1991. Characterization of the peripheral neuropathy in neonatal and adult mice that are homozygous for the fatty liver dystrophy (fld) mutation. *J. Biol. Chem.* 266:11955–64
58. Leiter EH, Kintner J, Flurkey K, Beamer WG, Naggert JK. 1999. Physiologic and endocrinologic characterization of male sex-biased diabetes in C57BLKS/J mice congenic for the fat mutation at the carboxypeptidase E locus. *Endocrine* 10: 57–66
59. Levak-Frank S, Radner H, Walsh A, Stollberger R, Knipping G, et al. 1995. Muscle-specific overexpression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice. *J. Clin. Invest.* 96:976–86
60. Li B, Nolte LA, Ju JS, Ho Han D, Coleman T, et al. 2000. Skeletal muscle respiratory uncoupling prevents diet-induced obesity and insulin resistance in mice. *Nat. Med.* 6:1115–20
61. Linhart HG, Ishimura-Oka K, DeMayo F, Kibe T, Repka D, et al. 2001. C/EBPalpha is required for differentiation of white, but not brown, adipose tissue. *Proc. Natl. Acad. Sci. USA* 98:12532–37
62. Liu S, Croniger C, Arizmendi C, Harada-Shiba M, Ren J, et al. 1999. Hypoglycemia and impaired hepatic glucose production in mice with a deletion of the C/EBPbeta gene. *J. Clin. Invest.* 103:207–13
63. Loftus TM, Jaworsky DE, Frehywot GL, Townsend CA, Ronnett GV, et al. 2000. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. *Science* 288:2379–81
64. Luetke NC, Lee DC, Palmiter RD, Brinster RL, Sandgren EP. 1993. Regulation of fat and muscle development by transforming growth factor alpha in transgenic mice and in cultured cells. *Cell Growth Differ.* 4:203–13
65. Marsh DJ, Holloper G, Kafer KE, Palmiter RD. 1998. Role of the Y5 neuropeptide Y receptor in feeding and obesity. *Nat. Med.* 4:718–21
66. Martinez-Botas J, Anderson JB, Tessier D, Lapillonne A, Chang BH, et al. 2000. Absence of perilipin results in leanness and reverses obesity in *Lepr<sup>db/db</sup>* mice. *Nat. Genet.* 26:474–79
67. Masuzaki H, Ogawa Y, Aizawa-Abe M, Hosoda K, Suga J, et al. 1999. Glucose metabolism and insulin sensitivity in transgenic mice overexpressing leptin with lethal yellow agouti mutation: usefulness of leptin for the treatment of obesity-associated diabetes. *Diabetes* 48: 1615–22
68. Matsui M, Motomura D, Karasawa H, Fujikawa T, Jiang J, et al. 2000. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. *Proc. Natl. Acad. Sci. USA* 97:9579–84
69. McLean JA, Tobin G. 1987. *Animal and Human Calorimetry*. Cambridge: Cambridge Univ. Press. 338 pp.
70. Miller KA, Gunn TM, Carrasquillo MM, Lamoreux ML, Galbraith DB, Barsh GS. 1997. Genetic studies of the mouse mutations mahogany and mahoganoid. *Genetics* 146:1407–15

71. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, et al. 1998. Life without white fat: a transgenic mouse. *Genes Dev.* 12:3168–81
72. Murray I, Havel PJ, Sniderman AD, Cianflone K. 2000. Reduced body weight, adipose tissue, and leptin levels despite increased energy intake in female mice lacking acylation-stimulating protein. *Endocrinology* 141:1041–49
73. Nagle DL, McGrail SH, Vitale J, Woolf EA, Dussault BJ Jr, et al. 1999. The mahogany protein is a receptor involved in suppression of obesity. *Nature* 398:148–52
74. Ogawa Y, Masuzaki H, Hosoda K, Aizawa-Abe M, Suga J, et al. 1999. Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. *Diabetes* 48:1822–29
75. Pedrazzini T, Seydoux J, Kunstner P, Aubert JF, Grouzmann E, et al. 1998. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. *Nat. Med.* 4:722–26
76. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, et al. 1999. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a <sup>1</sup>H-<sup>13</sup>C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. *Diabetes* 48:1600–6
77. Peterfy M, Phan J, Oswell GM, Xu P, Reue K. 1999. Genetic, physical, and transcript map of the fld region on mouse chromosome 12. *Genomics* 62:436–44
78. Peterfy M, Phan J, Xu P, Reue K. 2001. Lipodystrophy in the fld mouse results from mutation of a new gene encoding a nuclear protein, lipin. *Nat. Genet.* 27:121–24
79. Planas JV, Cummings DE, Idzerda RL, McKnight GS. 1999. Mutation of the RIIbeta subunit of protein kinase A differentially affects lipolysis but not gene induction in white adipose tissue. *J. Biol. Chem.* 274:36281–87
80. Qiu J, Ogus S, Lu R, Chehab FF. 2001. Transgenic mice overexpressing leptin accumulate adipose mass at an older, but not younger, age. *Endocrinology* 142:348–58
81. Qu D, Ludwig DS, Gammeltoft S, Piper M, Pelleymounter MA, et al. 1996. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. *Nature* 380:243–47
82. Reue K, Xu P, Wang XP, Slavin BG. 2000. Adipose tissue deficiency, glucose intolerance, and increased atherosclerosis result from mutation in the mouse fatty liver dystrophy (fld) gene. *J. Lipid Res.* 41:1067–76
83. Rodriguez De Fonseca F, Navarro M, Gomez R, Escuredo L, Nava F, et al. 2001. An anorexic lipid mediator regulated by feeding. *Nature* 414:209–12
84. Ross SR, Graves RA, Spiegelman BM. 1993. Targeted expression of a toxin gene to adipose tissue: transgenic mice resistant to obesity. *Genes Dev.* 7:1318–24
85. Salton SR, Ferri GL, Hahm S, Snyder SE, Wilson AJ, et al. 2000. VGF: a novel role for this neuronal and neuroendocrine polypeptide in the regulation of energy balance. *Front Neuroendocrinol.* 21:199–219
86. Sato M, Katsuura T, Yasukouchi A. 1979. The lower and upper critical temperatures in male Japanese. *J. Hum. Ergol. (Tokyo)* 8:145–53
87. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. 2000. Central nervous system control of food intake. *Nature* 404:661–71
88. Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E. 1998. Mice lacking melanin-concentrating hormone are hypophagic and lean. *Nature* 396:670–74
89. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. 1999. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. *Nature* 401:73–76
90. Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, et al. 1998.

- Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. *Genes Dev.* 12:3182–94
91. Smith SJ, Cases S, Jensen DR, Chen HC, Sande E, et al. 2000. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. *Nat. Genet.* 25:87–90
92. Sniderman AD, Maslowska M, Cianflone K. 2000. Of mice and men (and women) and the acylation-stimulating protein pathway. *Curr. Opin. Lipidol.* 11:291–96
93. Soloveva V, Graves RA, Rasenick MM, Spiegelman BM, Ross SR. 1997. Transgenic mice overexpressing the beta 1-adrenergic receptor in adipose tissue are resistant to obesity. *Mol. Endocrinol.* 11:27–38
94. Tanaka T, Yoshida N, Kishimoto T, Akira S. 1997. Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene. *EMBO J.* 16:7432–43
95. Tansey JT, Sztalryd C, Gruia-Gray J, Roush DL, Zee JV, et al. 2001. Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity. *Proc. Natl. Acad. Sci. USA* 98:6494–99
96. Tsao TS, Stenbit AE, Li J, Houseknecht KL, Zierath JR, et al. 1997. Muscle-specific transgenic complementation of GLUT4-deficient mice. Effects on glucose but not lipid metabolism. *J. Clin. Invest.* 100:671–77
97. Tsukiyama-Kohara K, Poulin F, Kohara M, DeMaria CT, Cheng A, et al. 2001. Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. *Nat. Med.* 7:1128–32
98. Ueno N, Inui A, Iwamoto M, Kaga T, Asakawa A, et al. 1999. Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. *Gastroenterology* 117:1427–32
99. Wang L, Shao J, Muhlenkamp P, Liu S, Klepcyk P, et al. 2000. Increased insulin receptor substrate-1 and enhanced skeletal muscle insulin sensitivity in mice lacking CCAAT/enhancer-binding protein beta. *J. Biol. Chem.* 275:14173–81
100. Weinstock PH, Bisgaier CL, Aalto-Setälä K, Radner H, Ramakrishnan R, et al. 1995. Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. *J. Clin. Invest.* 96:2555–68
101. Weinstock PH, Levak-Frank S, Hudgins LC, Radner H, Friedman JM, et al. 1997. Lipoprotein lipase controls fatty acid entry into adipose tissue, but fat mass is preserved by endogenous synthesis in mice deficient in adipose tissue lipoprotein lipase. *Proc. Natl. Acad. Sci. USA* 94:10261–66
102. West DB, Boozer CN, Moody DL, Atkinson RL. 1992. Dietary obesity in nine inbred mouse strains. *Am. J. Physiol. Regulatory Integrative Comp. Physiol.* 262:R1025–R32
103. West GB, Brown JH, Enquist BJ. 1997. A general model for the origin of allometric scaling laws in biology. *Science* 276:122–26
104. West GB, Brown JH, Enquist BJ. 1999. The fourth dimension of life: fractal geometry and allometric scaling of organisms. *Science* 284:1677–79
105. Wilkerson JE, Raven PB, Horvath SM. 1972. Critical temperature of unacclimatized male Caucasians. *J. Appl. Physiol.* 33:451–55
106. Winnier GE, Hargett L, Hogan BL. 1997. The winged helix transcription factor MFH1 is required for proliferation and patterning of paraxial mesoderm in the mouse embryo. *Genes Dev.* 11:926–40
107. Xiang X, Benson KF, Chada K. 1990.

- Mini-mouse: disruption of the pygmy locus in a transgenic insertional mutant. *Science* 247:967–69
108. Yamada M, Miyakawa T, Duttaroy A, Yamanaka A, Moriguchi T, et al. 2001. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. *Nature* 410:207–12
109. Young SG, Cham CM, Pitas RE, Burri BJ, Connolly A, et al. 1995. A genetic model for absent chylomicron formation: mice producing apolipoprotein B in the liver, but not in the intestine. *J. Clin. Invest.* 96:2932–46
110. Yu S, Castle A, Chen M, Lee R, Takeda K, Weinstein LS. 2001. Increased insulin sensitivity in Gsalpha knockout mice. *J. Biol. Chem.* 276:19994–98
111. Yu S, Gavrilova O, Chen H, Lee R, Liu J, et al. 2000. Paternal versus maternal transmission of a stimulatory G-protein alpha subunit knockout produces opposite effects on energy metabolism. *J. Clin. Invest.* 105:615–23
112. Yu S, Yu D, Lee E, Eckhaus M, Lee R, et al. 1998. Variable and tissue-specific hormone resistance in heterotrimeric Gs protein alpha-subunit (Gsalpha) knockout mice is due to tissue-specific imprinting of the gsalpha gene. *Proc. Natl. Acad. Sci. USA* 95:8715–20
113. Zhou X, Benson KF, Ashar HR, Chada K. 1995. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. *Nature* 376:771–74